Rain Therapeutics Inc. (RAIN)

Market Cap	40.02M
Revenue (ttm)	n/a
Net Income (ttm)	-72.26M
Shares Out	27.58M
EPS (ttm)	-2.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,081
Open	1.12
Previous Close	1.12
Day's Range	1.11 - 1.14
52-Week Range	0.82 - 14.48
Beta	0.22
Analysts	Buy
Price Target	6.87 (+502.63%)
Earnings Date	Nov 9, 2023

About RAIN

Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 23, 2021
• Employees: 63
• Stock Exchange: NASDAQ
• Ticker Symbol: RAIN

Analyst Forecast

According to 11 analysts, the average rating for RAIN stock is "Buy." The 12-month stock price forecast is $6.87, which is an increase of 502.63% from the latest price.

Price Target

$6.87

(502.63% upside)

Analyst Consensus: Buy